Insider Trading Alert - ESV, SMP And ICPT Traded By Insiders

Stocks with insider trader activity include ESV, SMP and ICPT
By TheStreet Wire ,

Yesterday, Nov. 4, 2015, 107 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $85.86 to $4,999,847.37.

Highlighted Stocks Traded by Insiders:

Ensco (ESV) - FREE Research Report

Swent James W Iii, who is Executive Vice President & CFO at Ensco, sold 59,189 shares at $17.81 on Nov. 4, 2015. Following this transaction, the Executive Vice President & CFO owned 15,932 shares meaning that the stake was reduced by 78.79% with the 59,189-share transaction.

The shares most recently traded at $18.13, up $0.32, or 1.77% since the insider transaction. Historical insider transactions for Ensco go as follows:

  • 4-Week # shares bought: 930
  • 4-Week # shares sold: 50,000
  • 12-Week # shares bought: 930
  • 12-Week # shares sold: 50,000
  • 24-Week # shares bought: 930
  • 24-Week # shares sold: 50,000

The average volume for Ensco has been 6.8 million shares per day over the past 30 days. Ensco has a market cap of $4.3 billion and is part of the basic materials sector and energy industry. Shares are down 38.76% year-to-date as of the close of trading on Wednesday.

Ensco plc provides offshore contract drilling services to the oil and gas industry worldwide. The company operates through three segments: Floaters, Jackups, and Other. The stock currently has a dividend yield of 3.29%. Currently, there is 1 analyst who rates Ensco a buy, 5 analysts rate it a sell, and 12 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ESV - FREE

TheStreet Quant Ratings

rates Ensco as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Ensco Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Standard Motor Products (SMP) - FREE Research Report

Sturdivant Frederick D, who is Director at Standard Motor Products, sold 1,500 shares at $44.16 on Nov. 4, 2015. Following this transaction, the Director owned 29,936 shares meaning that the stake was reduced by 4.77% with the 1,500-share transaction.

Gethin John P, who is Coo at Standard Motor Products, sold 10,000 shares at $44.18 on Nov. 4, 2015. Following this transaction, the Coo owned 19,447 shares meaning that the stake was reduced by 33.96% with the 10,000-share transaction.

Burks Dale, who is VP Global Sales & Marketing at Standard Motor Products, sold 2,056 shares at $44.04 on Nov. 4, 2015. Following this transaction, the VP Global Sales & Marketing owned 41,371 shares meaning that the stake was reduced by 4.73% with the 2,056-share transaction.

Nicholas Ray, who is Vp It & Cio at Standard Motor Products, sold 1,756 shares at $44.01 on Nov. 4, 2015. Following this transaction, the Vp It & Cio owned 28,931 shares meaning that the stake was reduced by 5.72% with the 1,756-share transaction.

The shares most recently traded at $44.46, up $0.45, or 1.01% since the insider transaction. Historical insider transactions for Standard Motor Products go as follows:

  • 4-Week # shares sold: 1,000
  • 12-Week # shares sold: 1,000
  • 24-Week # shares sold: 1,000

The average volume for Standard Motor Products has been 97,700 shares per day over the past 30 days. Standard Motor Products has a market cap of $1.0 billion and is part of the consumer goods sector and automotive industry. Shares are up 16.66% year-to-date as of the close of trading on Wednesday.

Standard Motor Products, Inc. manufactures and distributes replacement parts for motor vehicles in the automotive aftermarket industry. It operates in two segments, Engine Management and Temperature Control. The stock currently has a dividend yield of 1.34%. The company has a P/E ratio of 19.4. Currently, there are 2 analysts who rate Standard Motor Products a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on SMP - FREE

TheStreet Quant Ratings

rates Standard Motor Products as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, good cash flow from operations, growth in earnings per share and increase in stock price during the past year. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Standard Motor Products Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Intercept Pharmaceuticals (ICPT) - FREE Research Report

McMinn Rachel, who is Chief Strategy Officer at Intercept Pharmaceuticals, sold 125 shares at $160.24 on Nov. 4, 2015. Following this transaction, the Chief Strategy Officer owned 8,218 shares meaning that the stake was reduced by 1.5% with the 125-share transaction.

The shares most recently traded at $177.70, up $17.46, or 9.83% since the insider transaction. Historical insider transactions for Intercept Pharmaceuticals go as follows:

  • 4-Week # shares bought: 800
  • 4-Week # shares sold: 772
  • 12-Week # shares bought: 800
  • 12-Week # shares sold: 772
  • 24-Week # shares bought: 800
  • 24-Week # shares sold: 1,762

The average volume for Intercept Pharmaceuticals has been 457,700 shares per day over the past 30 days. Intercept Pharmaceuticals has a market cap of $4.4 billion and is part of the health care sector and drugs industry. Shares are up 18.42% year-to-date as of the close of trading on Wednesday.

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics to treat chronic liver and intestinal diseases utilizing its proprietary bile acid chemistry. Currently, there are 5 analysts who rate Intercept Pharmaceuticals a buy, 2 analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ICPT - FREE

TheStreet Quant Ratings

rates Intercept Pharmaceuticals as a

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, weak operating cash flow, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

Intercept Pharmaceuticals Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Loading ...